The identification of PC-1 as an NTPPPH expressed in cells derived from bone and cartilage may prove useful in furthering the understanding of the role of NTPPPH in physiologic and pathologic mineralization. (J. Clin. Invest. 1994. 94:560-567.)
Introduction
Membrane-bound enzyme activity that hydrolyzes the nucleoside monophosphate-pyrophosphate (phosphodiester I) bond in This work was partially presented in abstract form at the 1993 National Meeting of the American College of Rheumatology in San Antonio, TX on 10 November 1993. nucleotides (termed nucleotide pyrophosphohydrolase, abbreviated NTPPPH)' is expressed by osteoblasts, chondrocytes, and many other tissues (e.g., placenta, erythrocytes, fibroblasts, and hepatocytes [1] [2] [3] [4] ). NTPPPH participates in a cascade system of enzymes that hydrolyze nucleotides and nucleic acids to nucleosides (5) . This enzyme chain permits the salvage of nucleotides from extracellular fluids such as bile (5) and the uptake of nucleosides by cells that do not rely on synthesis of purines by the de novo pathway (6, 7) . Furthermore, scavenging of extracellular ATP released by injured and dividing cells may be necessary to prevent tissue injury triggered by ATP-induced cellular activation (8) .
In bone and cartilage, NTPPPH-catalyzed release of inorganic pyrophosphate (PPi) from nucleoside triphosphates provides a substrate for alkaline phosphatase-catalyzed generation of Pi and the crystallization of basic calcium phosphates (9) (10) (11) (12) (13) . The role of NTPPPH activity in physiologic endochondral mineralization is reinforced by the presence of NTPPPH in growth plate cartilage matrix vesicles (11) (12) (13) (14) (15) . NTPPPH activity is also linked to pathologic mineralization of adult hyaline articular cartilage, i.e., deposition of crystals of hydroxyapatite and other basic calcium phosphates (16) , and of calcium pyrophosphate dihydrate (CPPD) (in CPPD crystal deposition disease, or chondrocalcinosis) (17) (18) (19) (20) . Specifically, adult cartilage, like osteoblasts and growth plate cartilage, contains matrix vesicles (21, 22) , and the addition of an exogenous NTPPPH substrate (ATP) (23) to purified human adult cartilage matrix vesicles and to cartilage promotes the generation of CPPD-like crystals at physiologic pH (22, 24) .
Bone, cartilage, and other tissue NTPPPH enzymes (1-4, 9, 10, 25-27) share the capacity to recognize and hydrolyze the phosphodiester I bond in a variety of nucleotides and synthetic nucleoside substrates (e.g., nucleotide sugars, 3'-phosphoadenosine 5'-phosphosulfate), are "ectoenzymes" (i.e., functionally active on the extracellular face of the plasma membrane), and have an alkaline pH optimum.
The genes responsible for human bone and cartilage enzymes with NTPPPH activity are unknown. Importantly, one gene for another ectoenzyme, L/B/K alkaline phosphatase, can be expressed in different forms by hepatocytes, osteoblasts, and chondrocytes and certain granulocytic cells (28) . Thus, we hypothesized that, like certain other ectoenzymes, at least one NTPPPH species in osteoblasts and cartilage may be expressed by bone and cartilage cells, liver cells, and also serve as a marker for the state of differentiation of certain leukocytes (28, 29) . In this regard, we noted that the 5'-nucleotide phosphodiesterase I, PC-1, which was first recognized as a differentiation marker for murine antibody-secreting cells of B lymphocyte origin (30) (31) (32) (33) (34) , is also expressed in bovine hepatocytes (35) and that antibodies to PC-1 reacted with an undefined species by immunostaining in murine hyaline cartilage (36) . Cloning and functional characterization of PC-1 has been carried out recently by us (30, (32) (33) (34) 37) . We have demonstrated that PC-1 is an ectoenzyme that acts intracellularly and extracellularly and functions as a PPi-generating NTPPPH in both the intracellular and extracellular milieus (38) . Furthermore, PC-1 can be expressed in at least one soluble extracellular form (39) . Therefore, this study tested the hypothesis that cells from human bone and cartilage may share the capacity of hepatocyes and murine plasma cells to express the NTPPPH PC-1.
Methods
Tissue sources and culture conditions. A human osteosarcoma cell line with known osteoblast-like characteristics (U20S) (40) was obtained from American Type Culture Collection (Rockville, MD) and maintained in McCoy's 5A medium supplemented with 15% FCS, 1% penicillin-streptomycin, and 2 mM glutamine. A human hepatoma (HepG2) cell line also was obtained from the American Type Culture Collection repository. The murine plasmacytoma cell line, NS-1, which spontaneously expresses PC-1, was cultured as described previously by us (34) .
Cartilage and chondrocytes. The cartilages described in these experiments were obtained from the femoral condyles and tibial plateaus of osteoarthritis patients at the time of total knee joint replacement. All chondrocytes were first isolated within the laboratory of Dr. Martin Lotz (UCSD) by methods outlined previously in detail (41, 42) . After removal of blood and tissue debris, and to avoid chondrocyte culture contamination by other articular tissues, the articular surface was scraped gently with a scalpel from which any tissues stuck from the synovial surface or from synovial fluid were removed. Second, cartilage was collected only from noncalcified areas and from soft cartilage. Fibrillated cartilage was not used at all. Cartilage was minced with a scalpel and treated with trypsin (10% vol/vol) for 15 min in a 37°C waterbath. The samples were transferred to DME containing 5% FBS, penicillin-streptomycin-fungizone, and 2 mg/ml clostridial collagenase type IV (Sigma Immunochemicals, St. Louis, MO) and digested for 3 h on a gyratory shaker until the tissue fragments were dissolved.
Subcultured cells (passages 1-5) were trypsinized from T175 flasks and plated in 96-well plates at 5,000-20,000 cells/well in DME 1% FBS. The media were removed, the wells were washed twice with serum-free DME, and culture was continued in DME supplemented with L-glutamine and antibiotics.
Synovial fluids. Human knee synovial fluids were obtained by informed consent during diagnostic or therapeutic procedures in noninflammatory conditions (osteoarthritis, internal derangement). All were nonhemorrhagic, noninflammatory by transparency and viscosity, and free of crystals by polarized light microscopy. All fluids were treated with EDTA (5 mM), PMSF (100 MM) and aprotinin (0.01%), and testicular hyaluronidase ( 100 Mg/ml) and centrifuged (6,900 g for 30 min at 4°C) to remove cells and particulates.
5'-Nucleotide phosphodiesterase I assay. The assay was performed using as substrate 1 mM p-nitrophenyl-thymidine 5'-monophosphate (PNTM) (Sigma Immunochemicals) in 50 mM Hepes-buffered DME containing 1.6 mM MgCl2, pH 8.0, in a volume of 0.5 ml to which 0.05 ml of sample was added for 1 h (10, 27) . The assay was halted by addition of 4 vol of 100 mM NaOH, and absorbance at OD 405 was determined. Specific enzyme activity was measured against a standard curve of p-nitrophenol and expressed in Units (1 U was equivalent to 1 pmol of substrate hydrolyzed per h).
Anti-PC-I antibodies. We used two previously described rabbit polyclonal antisera to recombinant murine PC-I clones (3-1 and 5) and an antiserum to chromatographically purified, denatured mouse PC-I (ADPC-1) (34) . In addition, two antisera to recombinant human PC-1 (R1040 and R1042) were generated by immunizing rabbits with a synthetic peptide consisting of the COOH-terminal 15 amino acids of human PC-1, coupled to bovine serum albumin using glutaraldehyde, and emulsified in complete Freund's adjuvant. A 50% saturated ammonium sulfate cut was isolated from each anti-human PC-I antiserum and from control nonimmune rabbit serum and was washed twice by passive adsorption to an equal volume of human erythrocytes before being used.
Western blot detection of PC-I. Lysates of washed cells were generated by treatment for 10 min in 1% Triton X-100. SDS-PAGE and Western blotting were performed largely by previously described methods (43 with the kit's chemiluminescent reagent in assay buffer for 10 min and then exposed to x-ray film for 10-30 min.
Immunoprecipitation of PC-I activity. Cells were spun down and washed in 150 mM NaCl, 10 mM Tris (pH 7.6) and resuspended for 24 h at 4°C in the same buffer to which 0.1% Triton X-100 was added.
Cell lysates (40 Mg protein in a total volume of 0.02 ml) were incubated with 0.01 ml of nonimmune rabbit serum or the same volume of anti-PC-I antisera (a combination of 0.002 ml each of R1040, R1042, 3-1, 5, and ADPC-1) overnight at 4°C. Staph protein A-Sepharose, 0.05 ml of a 50% suspension, was then added for 2 h at 4°C with constant agitation, then this suspension was sedimented in a Stratagene picofuge (model #400550) for 30 s. The beads were then washed twice in 1.0 ml of the Tris/NaCl buffer, as above. To the pelleted beads, or the supernatant (0.05 ml), was added 0.5 ml of buffer containing 1 mM PNTM, 15 mM Hepes, and phenol-free DME, pH 7.4, for 1 h.
For [35S]methionine labeling, confluent U20S cells (-0.5 X 106 cells in 10 ml) were labeled with 800 pCi [35S]methionine (NEN, Boston, MA) for 6 h in methionine-free DME (GIBCO BRL, Baltimore, MD) and chased for 24 h in complete DME medium in the presence or absence of recombinant TGF/6 (1 ng/ml) for 24 h. Washed, harvested monlayers were lysed in Triton X-100 (1I%) for 1 h on ice. The cell lysates (0.5 ml) were precleared with protein G-Sepharose beads (0.05 ml of a 10% solution) (Zymed Laboratories, Inc., South San Francisco, CA) by a 2-h incubation at 4°C, followed by centrifugation at 5,000 g for 30 s. Antibodies (0.01 ml total as above) were added for 18 h. Proportionate concentrations of nonimmune sera were used as controls. Polypeptides were precipitated after adding 0.1 ml of a 10% solution for 1.5 h at 4°C. Pellets were washed three times in 5 vol PBS, boiled, and then analyzed by SDS-PAGE. After staining with Coomassie blue, the gels were treated with Amplify (Amersham Corp., Arlington Heights, IL) for I h, dried, and exposed to Kodak XAR film at -70°C for 4 h.
Detection of PC-I mRNA. A full-length human PC-I cDNA hybridization probe in pBluescript SK-was constructed by ligation of two partial cDNA clones from placental libraries (33) . Restriction enzyme mapping and sequencing of the extreme 5' end of the human PC-i cDNA construct confirmed identity with human PC-1.
For Northern blotting, mRNA was purified using the Pharmacia LKB Biotechnology Inc. (Piscataway, NJ) "quick mRNA prep kit" according to the manufacturer's instructions. Where indicated, total RNA was isolated by a previously described method using guanidinum isothiocyanate (41 For RNA-PCR, we selected primers that spanned more than one intron (based on knowledge of human PC-i 5' intron-exon structure [39] ). We prepared a double-stranded cDNA template from I07 U20S cells by isolating 5 /sg of total RNA and reverse-transcribing it using random primers and the Invitrogen (San Diego, CA) RT-cDNA PCR kit. One-twentieth of the cDNA was used as a template for two rounds of PCR reaction, using the 5' and 3' primers for PC-i (300 ng each) as indicated below, and 250 /sM dNTPs, and 2.5 U of AmpliTaq (PerkinElmer/Cetus, Norwalk, CT) in 1.5 mM magnesium containing-buffer (conditions: an initial 4-min run at 940C before starting, then 940C at 2 min, 550C at 2 min for annealing, and 720C at 3 min for extension. The final extension, at the end of 40 as smaller soluble peptides that may be generated via proteolysis (39) . PC-I polypeptides in murine plasmacytoma cells were confirmed (34, 37) to be expressed as a predominant full-length species with a molecular mass of -115-130 kD and as a minor species of -230, 90, and 60 kD (Fig. 1, lane 3 (Fig. 1, lanes  I and 2) .
In human articular chondrocytes, antimurine recombinant PC-1 antibodies also detected low abundance polypeptide species with estimated molecular masses of 260, 130, and 60 kD (Fig. 2) . In all cells tested, the PC-I cross-reactive polypeptides of 60 kD became more abundant, and the higher molecular mass species became less abundant as samples were stored for longer periods of time (data not shown), suggesting that the 60-kD species might arise from degradation of parent PC-1 molecules.
Thus, the capacity for PC-1 expression appeared to be shared by murine plasma cells, human hepatoma cells, and human osteosarcoma cells and chondrocytes. PC-1 also was expressed by whole cartilage in the joint space in vivo. Specifically, knee articular cartilage homogenates from osteoarthritis patients contained polypeptides compatible with full-length PC-1 species (Fig. 3, lanes 1 and 2) . Smaller polypeptides that were cross-reactive with PC-1 were also present in cartilage homogenates (Fig. 3, lanes I and 2) . Furthermore, in the course of storing cartilage samples, as with the storage of lysates of cultured cells discussed above, we noted that PC-1 cross-reactive polypeptides of 60 kD became more abundant, and larger polypeptides became less plentiful with time (data not shown).
Because articular cells can export products into the synovial fluid, we ascertained whether PC-1 polypeptides were detectable in human synovial fluids. Eight nonhemorrhagic knee synovial fluids (four uncomplicated osteoarthritis, four internal derangements) all contained PC-I cross-reactive species, predominantly in the form of a 60-kD polypeptide (Fig. 4) 115, and 72 kD. (Fig. 4) ; the nature of this cross-reactive material was not investigated. PC-I is constitutively a low abundance mRNA in human chondrocytes and osteosarcoma cells. The active site of PC-I is highly homologous to that of intestinal alkaline phosphodiesterase (45, 46) , suggesting that PC-i could share a conserved enzymatic domain with related but nonidentical enzymes in other tissues. Therefore, to verify that PC-I was being expressed in chondrocytes, we attempted to detect transcription of PC-1. PC-i is expressed as a very low abundance mRNA in certain tissues (33, 47) . For example, Northern blot hybridization to 10 jLg of isolated mRNA was previously required to confirm PC-I mRNA expression in human fibroblasts under resting conditions (47) . Under similar conditions (Fig. 5) , using 10 jIg of mRNA, we also detected PC-I mRNA (3. Grossly noninflammatory synovial fluids (25 Ag of protein) from eight separate patients were isolated and treated as described in Methods and studied by SDS-PAGE and Western blotting using antiserum 3-1 as described above. Lanes 1-4 were from patients with osteoarthritis; lanes 5-8 were from patients with internal derangements. Arrows indicate polypeptides of 60 kD in all specimens and high molecular mass material that did not enter the gel in specimens 1-3 and 8. Faint PC-I polypeptides of 130 kD were seen in lanes 6-8 but did not reproduce well in photographs. 
PC-I was further verified in chondrocytes and osteosarcoma cells via nested RNA-PCR.
To detect PC-1 by RNA-PCR, we selected primers likely to span at least one intron, based on our knowledge of PC-1 5 ' intron-exon structure (39) . Using two rounds of PCR, with nested primers, we amplified PC-I from double-stranded cDNA generated from random-primed, reverse-transcribed total RNA from human monolayer-cultured chondrocytes. Under these conditions, RNA-PCR detected PC-1 as a product of the predicted (370 bp) length in osteosarcoma cells and hepatoma cells (Fig. 6, lanes I and 3) and in murine plasmacytoma (NS-I cells) (Fig. 7 B, lane 4) . RNA-PCR verified PC-1 mRNA expression in human chondrocytes (Fig. 7 B, lane 1) . Chondrocytes cultured in the presence of 200 nM dexamethasone (which can enhance PC-I transcription in certain mouse plasmacytoma cells [34] ) and the cartilage growth factor, TGF,61 (Fig. 7 product from A, lane 2, as negative control.
( Fig. 7 A) . The specificity of PC-i detection by RNA-PCR was confirmed by demonstrating that the 370-bp products of the PC-i RNA-PCR reaction, but not the 160-bp products of the L30 RNA-PCR reaction, hybridized with a full-length human PC-I cDNA probe (Fig. 7 C) .
Therefore, PC-I was constitutively expressed as a low abundance mRNA by cultured osteosarcoma cells and articular chondrocytes.
Regulation TGF,61 significantly increased cellular NTPPPH activity in U20S osteosarcoma cells (Table II) , in association with the detection of de novo synthesized [35S ] methionine-labeled PC-1 polypeptides (Fig. 8 A) . Analysis of PC-1 gene expression in osteosarcoma cells by RNA-PCR suggested a TGF/3-induced increase in PC-I mRNA (Fig. 8 B) . This was confirmed by noting upregulation of PC-I mRNA (3.8 kb) by Northern blotting (Fig. 8, C and D) where PC-I mRNA could be detected easily in the TGF/3-stimulated cells but not control cells using only 15 Mug of total RNA. Thus, TGF,3 upregulated both PC-I gene expression and 5'-nucleotide phosphodiesterase I/ NTPPPH in osteosarcoma cells. and then Triton-lysed, and 5'-nucleotide phosphodiesterase I activity was measured in aliquots (n = 3) that contained 50 jsg of cellular protein, as described above. The results indicated were from cells sampled at the same passage as in the experiment outlined in Fig. 8 , A-D (results were similar in three other experiments). * P < 0.01 for TGFI3
relative to control.
Discussion
NTPPPH activity is implicated in physiologic and pathologic skeletal and cartilage mineralization (21, 22 (33, 34, 39) . In this regard, the appearance of less than full-length cross-reactive species of PC-I (including the 60-kD species) increases with time in storage in lysates of osteosarcoma cells and chondrocytes and in cells transfected with PC-1 cDNA (38), suggesting possible degradative events (data not shown). Thus, it will be important in further studies to define potential proteolytic processing and/ or alternative splicing of PC-I in these tissues and to define the enzymatic properties of individual processed PC-1 polypeptides.
Interestingly, various soluble forms of 5 '-nucleotide phosphodiesterase I have been described in serum (49) (50) (51) (53) . In this regard, the potential relationship of PC-1 to cartilage and osteoblast-derived matrix vesicle NTPPPH will be an important area to examine further in depth. Regulation ofPC-I expression. The amount of PC-I mRNA is constitutively quite low in human fibroblasts and in certain other tissues (33, 47) . We similarly observed low abundance PC-I mRNA expression in resting osteosarcoma cells and chondrocytes (Fig. 5) . Under these conditions, our results suggest that RNA-PCR may be a valuable approach to evaluate PC-1 transcription (Figs. 6 and 7) . PC-1 was also a low abundance protein product in cultured chondrocytes and osteosarcoma cells. In this regard, plasmacytoma cells (Fig. 1, lane 3) , which have high PC-I specific activity, similarly have a low abundance of PC-1 protein, i.e., only -10 pHg of PC-1 can be purified per 100 g of plasmacytoma tumors (34).
TGFP1i, a growth and repair factor present in bone and cartilage matrix (48, 54) , has recently been observed to significantly increase NTPPPH activity in primary cultures of osteoblast-like cells from human femoral trabecular bone, an effect attenuated by inhibitors of transcription and of translation (48) .
We noted that TGF,61 also induced upregulation of 5 '-nucleotide phosphodiesterase I/NTPPPH in osteoblast-like U20S osteosarcoma cells (Table II) and we demonstrated that the PC-1 expressed by osteosarcoma cells was enzymatically functional (Table I ). We also demonstrated that osteosarcoma cells responded to TGFJ31 by clearly increasing PC-I polypeptide production and PC-1 mRNA expression (Fig. 8) .
The contrast between the marked increase in PC-1 mRNA transcripts (Fig. 8) (6, 9) for different substrates. Importantly, the effect of TGFl on NTPPPH in primary osteoblast-like cultures is characterized by a progressive rise (that reaches a twoto threefold increase) in extracellular PPi generation in the presence of added extracellular ATP over 72 h in culture (48) . The sustained elevation of PPi concentration under these conditions may be partially mediated by an inhibitory effect on PPi-splitting alkaline phosphatase activity (48) . The development of a specific immunoassay for PC-I should prove useful in determining whether small increases in the polypeptide concentration of PC-I in cells are sufficient to induce large increases over time in the degradation of individual NTPPPH substrates such as ATP.
Interestingly, the effects of TGF,3 on NTPPPH activity may be tissue specific. Specifically, human dermal fibroblast NTPPPH activity (which appears largely attributable to PC-1 [47] ) is not upregulated by TGF,5 (48) . In contrast, Rosenthal et al. (55) have shown that TGF3 affects a modest (-10%) but significant increase in plasma membrane NTPPPH in porcine articular cartilage chondrocytes. We addressed only qualitative expression of PC-1 mRNA in chondrocytes, detecting expression by RNA-PCR after TGF/3 stimulation (Fig. 7) . More detailed assessment of the effects of TGF,6 and other growth and repair factors on PC-1 expression in fibroblasts and chondrocytes is an important area for further study.
NTPPPH/PC-1 is expressed as an ectoenzyme on not only the plasma membrane but also in the rough endoplasmic reticulum (31, 37) . Importantly, upregulation of PC-1 expression by cDNA transfection markedly increases not only extracellular PPi generation but also intracellular PPi generation (38) . Furthermore, the latter effect does not require supplementation with exogenous ATP (38) . Thus, it will be important in future studies to test the hypothesis that transcriptional upregulation of PC-I by TGF3 and other bone and cartilage growth factors may be one mechanism by which cells specialized for mineralization modulate rapid increases in PPi generation.
In conclusion, the identification of PC-1 as an NTPPPH expressed by cells derived from cartilage and bone may provide a novel molecular tool to further understand the role of NTPPPH expression in both physiologic and pathologic bone and cartilage mineralization.
